Palantir Technologies prepares to release its fourth-quarter financial results, with analysts forecasting significant growth despite recent pressure on its stock and broader software sector concerns.
A Foxboro woman's two-year struggle with a defective high-end oven underscores the enduring power of state consumer protection laws, even after a manufacturer's warranty expires.
Fifth Third Bancorp has finalized its acquisition of Comerica in under four months, a swift consolidation that underscores a new era of accelerated bank mergers driven by regulatory shifts and the relentless pursuit of scale.
Albertsons' retail media division opens its first NYC office and unveils a new logo, signaling a significant expansion and strategic push to deepen ties with advertisers and agencies in the competitive retail media landscape.
Newly released video evidence shows Islamic State fighters moving unchallenged among aircraft at Niamey's Diori Hamani International Airport, igniting regional tensions and raising urgent questions about security in the Sahel.
Facing pressure from both investors and regulators, banks and wealth managers are turning to pass-through voting mechanisms to reclaim shareholder influence and align stewardship with client values, even within passively managed funds.
As the Federal Reserve prepares for a potential policy shift in 2026, analysts flag real estate, financials, energy, and consumer discretionary as vulnerable sectors. Structural challenges and changing macroeconomic conditions could pressure performance despite broader market gains.
As the 2027 deadline for Swift's Case Management standard approaches, banks face a strategic inflection point. Early adopters of native processing are poised to unlock operational resilience and revenue growth, while laggards risk entrenched inefficiency and competitive decline.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Despite promising mid-stage clinical data and billion-dollar sales potential for its mRNA pipeline, Arcturus Therapeutics (ARCT) is trading near its cash value—a signal the market is assigning near-zero odds to its success. This stark disconnect has analysts debating whether the biotech firm is a glaring mispricing or a high-risk bet.
Advance Auto Parts (NYSE:AAP) remains a favored pick among hedge funds, even as Wall Street analysts offer conflicting price targets and ratings ahead of anticipated 2026 demand growth.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Despite a recent sales miss, AutoZone (AZO) is doubling down on store growth, drawing mixed analyst reactions. JPMorgan remains bullish with an $4,100 price target, while Wolfe Research downgraded the stock, highlighting the complex landscape for the auto parts retailer.
Global commodity markets opened the new week and month deep in negative territory, with the energy sector plummeting an average of 7.3% and grains facing headwinds from shifting trade flows and seasonal pressures.
